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INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is limited by conditioning toxicity, graft rejection, graft-versus-host disease (GVHD), and insufficient graft-versus-tumor (GVT) effects.
Reduced-intensity conditioning decreases toxicity but promotes mixed chimerism(1) and graft rejection or tumor progression (2) . Intensified post-HCT immune suppression or graft T cell depletion reduces GVHD but can decrease GVT effects(3); furthermore, donor lymphocyte infusion (DLI) using unmanipulated T cells can mediate GVT effects but also mediate GVHD(4). To address these limitations, we conducted a pilot clinical trial of immune-selective conditioning, in vivo sirolimus GVHD prophylaxis, and multiple infusions of DLI products manufactured ex vivo in sirolimus.
Conditioning varies from myeloablative to reduced-intensity to non-myeloablative(5).
However, an ultra-low intensity platform that avoids any neutropenia has not been fully explored. Stem cell engraftment may not be fully reliant on conditioning-induced "marrow space"(6); we thus reasoned that non-neutropenic conditioning would permit stem cell engraftment if immunologic rejection was prevented. Conditioning also reduces tumor burden, but this rationale is weakened in chemotherapy refractory settings. Finally, because conditioning reduces graft rejection, it should be directed towards host T cells that primarily mediate rejection(7). An immune-selective regimen that avoided neutropenia would yield direct safety advantages and also reduce conditioning-related induction of GVHD(8).
We used pentostatin plus daily cyclophosphamide (Cy) conditioning that was personalized based on efficacy (absolute lymphocyte count [ALC] reduction) and safety (absolute neutrophil count [ANC] preservation). Pentostatin was used as transplant conditioning with neutropeniainducing doses of total body irradiation(9, 10) or busulfan(11). Pentostatin plus bolus-dose Cy T-Rapa cells were apoptosis-resistant, prevented rejection, and were effective against GVHD(20-22). In the previous trial, one T-Rapa infusion was associated with: conversion of mixed chimerism towards full donor elements; a low rate of acute GVHD; and GVT effects against lymphoid malignancy. In the current trial, we used T cellreplete allografts augmented with T-Rapa DLI at days 0, 14, and 45 post-HCT.
GVHD prophylaxis typically consists of a calcineurin inhibitor plus a second agent(23).
Previously, we used cyclosporine plus short-course, standard-dose sirolimus through d 14 post-HCT. Sirolimus inhibits mTOR and thereby has an anti-tumor mechanism, including mediation anti-lymphoma effects post-HCT(24). Because the degree of mTOR inhibition correlates with sirolimus concentration (25) , higher dosing may optimize anti-tumor effects. Sirolimus has substantial toxicity after intensive conditioning (26) or with calcineurin inhibitors (27) . However, Campath plus high-dose sirolimus (target, 30 ng/ml) after non-myeloablative conditioning was safe and effective for GVHD prevention (28) . We thus reasoned that high-dose, single-agent sirolimus would be safe after immune selective PC conditioning and represent adequate GVHD prophylaxis after T cell-replete transplant and multiple T-Rapa DLI.
We evaluated this therapy in refractory metastatic renal cell carcinoma (RCC), thereby providing a rationale for lymphocyte-specific conditioning intended for rejection abrogation rather than tumor reduction. Metastatic RCC is susceptible to an allogeneic GVT effect that is generally associated with GVHD, as described by the National Heart Lung and Blood Institute(29) and a summation report from 21 European countries (30) . However, GVT effects were not observed in a separate study (31) . Thus, more robust methods of harnessing GVT effects and modulating GVHD are required in RCC patients. Finally, metastatic RCC can respond to temsirolimus (32) , thus suggesting that high-dose sirolimus might yield an anti-tumor benefit.
MATERIALS AND METHODS

Clinical Trial Design and Implementation
The trial (schema, Figure 1 The primary study objective was to determine whether this transplant approach could safely achieve clinical regression of metastatic RCC (goal of ruling out a 20% overall PR/CR rate in favor of a 40% PR/CR rate); using a Simon two-stage design, the occurrence of ≥3 responses in the first 12 evaluable patients would be required to proceed to the second stage of study design.
Organ toxicity was evaluated by NCI Common Toxicity Criteria (version 2.0). GVHD was evaluated using acute (34) and chronic grading (35) ; acute GVHD onset within the first 100 days post-HCT was considered classical acute(34) whereas onset after day 100 was considered late acute (35) . Disease responses were evaluated by computed tomographic measurements and according to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee criteria.
Alloengraftment was monitored using variable N-terminal repeat PCR assays on total PBMC, enriched T cells (CD3-selected), or enriched myeloid cells (CD15-selected).
Immune Monitoring
Research. Plasma IL-7 and IL-15 levels were measured by bioplex assay (EMD Millipore; Billerica, MA). Cytokine assays were performed on cryopreserved peripheral blood samples taken pre-and post-conditioning and at various points post-HCT. As described(19), cells were thawed and stimulated with anti-CD3/28 beads and resultant supernatants were tested for cytokine content by multi-plex assay (EMD Millipore); flow cytometry for transcription factor and differentiation marker expression was also performed as previously described. The statistical significance of the absolute difference or the relative difference from the baseline (or earlier) values was determined using a Wilcoxon signed rank test. Whether the absolute difference or relative difference was selected for evaluation depended on which one was less dependent on the baseline values. All pvalues are reported without formal adjustment for multiple comparisons. In view of the number of tests performed, only p-values <0.01 would be interpretable as being associated with significant differences, while p-values between 0.01 and 0.05 would suggest strong trends. Table I ( Fig. 3a) . Transplantation of T cell replete allografts plus the first infusion of T-Rapa cells thus yielded immediate donor T cell engraftment; however, chimerism values remained relatively constant during sirolimus therapy in spite of multiple T-Rapa DLI. After discontinuation of sirolimus at day 60 post-HCT, donor T cell chimerism increased to a median value of 92% (range, 21 to 100). The PC regimen yielded limited donor myeloid engraftment (Fig. 3b) : median donor myeloid chimerism at days 7 and 14 post-HCT were each 0% (ranges: 0 to 1; 0 to 27).
RESULTS
PATIENT CHARACTERISTICS
Median percent donor myeloid chimerism increased modestly during sirolimus therapy, with values at days 28, 45, and 60 post-HCT of 13 (range, 4 to 50), 18 (range, 11 to 67), and 26 (range, 13 to 76). After discontinuation of sirolimus at day 60 post-HCT, donor myeloid chimerism increased to a median of 61% (range, 16 to 100). The two patients with the lowest T cell chimerism through day 100 post-HCT also had the lowest myeloid cell chimerism; both of these patients received each of the planned T-Rapa DLI plus additional unmanipulated DLI.
In experimental models, rapamycin therapy increased CD8 + T cell memory responses(38).
Given these data, we measured naïve, central memory, and effector memory CD4 + and CD8 + T cell subsets during and after sirolimus therapy: these subsets did not differ substantially when comparing the day 14, day 60, and day 100 post-HCT time points (Fig. 3c) .
T CELL PHENOTYPE POST-HCT
Previously, T-Rapa DLI increased Th1-and Th2-type responses by transcription factor analysis and cytokine secretion assays(19). Similar to this initial trial, we found a preponderance 
vulvo-vaginal involvement. By day 60 post-HCT, in spite of high-dose sirolimus therapy, four of 10 patients had progressive disease by RECIST criteria; five additional patients developed progressive disease by day 100 post-transplant. One patient continues to have stable disease more than four years post-transplant (collecting duct carcinoma). Each of the nine protocol deaths was primarily attributable to progressive RCC; one case was additionally attributable to late acute gut GVHD and CMV enteritis that occurred after multiple unmanipulated DLI. Several factors likely contributed to the lack of GVT effects. First, responses against RCC after allogeneic HCT preferentially occur in patients with less than three metastatic sites(48); our study was comprised of heavily pre-treated patients (median, 3.5 prior regimens) with extensive metastatic burden (median, 3.5 sites). Second, our hypothesis that high-dose sirolimus would limit tumor progression was not confirmed, as nine of 10 patients had progressive disease during or shortly after sirolimus therapy. Third, high-dose sirolimus was counter-productive due to promotion of stable mixed chimerism [which was seen in a previous study of high-dose sirolimus (28) ] and due to inhibition of Th1-type cells [which are necessary for murine GVT effects against RCC cells (49)]. Fourth, the low donor myeloid engraftment after PC conditioning was likely counter-productive, as donor APC contribute to GVT effects in experimental models(50). Finally, previous clinical trials have indicated that GVT effects against RCC are associated with clinical GVHD (29, 30) .
The overall transplant approach we evaluated was not suitable for therapy of refractory cancer, but may be advantageous for therapy of non-malignant disease. These results provide a cautionary note in terms of combining adoptive T cell therapy with high-dose sirolimus therapy, which did not prevent tumor progression and limited post-transplant T cell effects. Our future investigations will continue to incorporate ultra-low intensity conditioning such as the PC regimen as a safe platform for evaluation of novel T cell therapy products. However, such platforms will incorporate calcineurin inhibitors as GVHD prophylaxis to avoid the in vivo tolerizing effects of sirolimus therapy.
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